Filing Flows › Acadia Pharmaceuticals (ACAD) › Q2 2026 › vs Q2 2025
Acadia Pharmaceuticals (ACAD) Q2 2026 vs Q2 2025 (year over year)
Acadia Pharmaceuticals's revenue rose $43.4M (+16%) from $265M in Q2 2025 to $308M in Q2 2026. Operating margin 12.3% against 12.2% (+0.0 pts).
Acadia Pharmaceuticals, Q2 2026: revenue $308M (+16% year over year), operating margin 12.3%, net earnings $31.5M, operating cash flow $101M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 12.3% | 12.2% | +0.0 pts |
| Net margin | 10.2% | 10.1% | +0.1 pts |
| Free cash flow margin | 31.1% | 24.1% | +7.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $308M | $265M | $43.4M | +16% |
| Other income, net | $8.6M | $7.8M | $800K | +10% |
| Operating profit | $37.8M | $32.4M | $5.5M | +17% |
| Costs & expenses | $270M | $232M | $37.9M | +16% |
| Pre-tax earnings | $46.5M | $40.2M | $6.3M | +16% |
| Cost of revenue | $28.3M | $20.7M | $7.6M | +37% |
| Research & development | $81.6M | $78.0M | $3.6M | +5% |
| SG&A | $160M | $134M | $26.7M | +20% |
| Net earnings | $31.5M | $26.7M | $4.8M | +18% |
| Income tax | $15.0M | $13.5M | $1.4M | +11% |
| Depreciation & amortization | $3.2M | $2.9M | $222K | +8% |
| Share-based compensation | $16.9M | $14.3M | $2.6M | +18% |
| Working capital & other | $49.2M | $20.0M | $29.2M | +146% |
| Operating cash flow | $101M | $64.0M | $36.8M | +58% |
| Free cash flow (OCF − capex) | $95.7M | $63.7M | $32.0M | +50% |
| Capital expenditures | $5.1M | $297K | $4.8M | 17× |
Questions
How much did Acadia Pharmaceuticals's revenue grow year over year in Q2 2026?
Acadia Pharmaceuticals's revenue rose $43.4M (+16%) from $265M in Q2 2025 to $308M in Q2 2026. Operating margin 12.3% against 12.2% (+0.0 pts).